Radioprotective and radiomitigative effects of BP-C2, a novel lignin-derived polyphenolic composition with ammonium molybdate, in two mouse strains exposed to total body irradiation

• Published in: International journal of radiation biology 2018-02, Vol.94 (2), p.114-123
• Main Authors: Bykov, Vladimir N., Drachev, Igor S., Kraev, Sergey Yu, Maydin, Mikhail A., Gubareva, Ekaterina A., Pigarev, Sergey E., Anisimov, Vladimir N., Baldueva, Irina A., Fedoros, Elena I., Panchenko, Andrey V.
• Format: Article
• Language: English
• Subjects: acute radiation syndrome; Metal-containing polyphenolic complex; mouse model; radiation mitigation; radiomitigator; total body irradiation
• ISSN: 0955-3002; 1362-3095
• DOI: 10.1080/09553002.2018.1416204

Purpose: There remains an unmet medical need for radioprotective and mitigative agents. BP-C2 is a novel lignin-derived polyphenolic composition with ammonium molybdate, developed as radioprotector/radiomitigator. Objectives: The present study evaluated BP-C2 for the mitigation of acute radiation syndrome (ARS). Methods: A total-body irradiation mouse model (TBI, 4.0-8.0 Gy) was used in the study. Results: In a 30-day survival study, performed in CBA mice, BP-C2, at a dosage of 81.0 mg/kg, improved survival (dose reduction factor (DRF) = 1.1) and increased the formation of endogenous spleen colony-forming units (CFU). In C57BL/6 mice, BP-C2, when administered daily for 7 days, starting 24 hours after TBI, also improved survival. In animals irradiated with 5.0 Gy, BP-C2 increased the number of CFUs (6.7 ± 5.1) compared to the 5.0 Gy placebo group (2.3 ± 2.3, p = .0245). The number of surviving intestinal crypts was maintained in the 5.0 Gy BP-C2 group (133.7 ± 13.9), in contrast to the 5.0 Gy placebo group (124.2 ± 10.5, p